An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide selected from the group consisting of: (a) a peptide represented by formula (1): H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H (1) (b) a peptide represented by formula (2): R-Ile-Pro-His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH (2) wherein R is the same as drefined above; (c) a peptide represented by formula (3): R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH (3) wherein R is the same as defined above; (d) a peptide represented by formula (4): H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH (4) (e) a peptide represented by formula (5): R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH (5) wherein R is the same as defined above; and (f) a peptide represented by formula (6): H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH (6) as a hapten, with a carrier in the presence of a hapten-carrier binding agent.
通过向哺乳动物注射人类白血病病毒相关肽抗原制备的抗原,收集哺乳动物体内产生的
抗体获得的人类白血病病毒相关肽
抗体,所述抗原由以下组成的人类白血病病毒相关肽反应制备而成:(a) 由公式(1)表示的肽:H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H (1) (b) 由公式(2)表示的肽:R-Ile-Pro-His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH (2),其中R与上述定义相同;(c) 由公式(3)表示的肽:R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH (3),其中R与上述定义相同;(d) 由公式(4)表示的肽:H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH (4);(e) 由公式(5)表示的肽:R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH (5),其中R与上述定义相同;以及(f) 由公式(6)表示的肽:H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH (6)作为半抗原,在半抗原-载体结合剂存在的情况下与载体共同存在。